Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Niagen Bioscience IncNASDAQ: NAGE
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 85.3% from a year ago
Net receivables stood at $13.07M at the end of Q1 FY2026, up 85.3% from a year earlier and up 34.2% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Net receivables amounted to 11.4% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +85.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 9.74M USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +16.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.74M | +25.4% |
| FY2024 | 2024-12-31 | 7.77M | +48.4% |
| FY2023 | 2023-12-31 | 5.23M | -38.3% |
| FY2022 | 2022-12-31 | 8.48M | +62.3% |
| FY2021 | 2021-12-31 | 5.23M | — |
Net Receivables vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's Mar 2026 net receivables of $13.07M is the 4th highest of the 10 companies compared; the peer median is $10.94M.
- Its year-over-year change of +85.3% is the 2nd highest of 8, against a peer median of +20.2%.
- Net receivables amounts to 11.4% of total assets for NAGE, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $62.54M | +1.6% | +5.3% | 17.3% | |
| Mar 2026 | $49.95M | +20.2% | +8.7% | 9.9% | |
| Mar 2026 | $22.1M | +75.1% | +41.0% | 7.9% | |
NAGENiagen Bioscience Inc | Mar 2026 | $13.07M | +85.3% | +4.7% | 11.4% |
| Dec 2025 | $11.3M | — | — | 3.4% | |
| Mar 2026 | $10.94M | -42.9% | -3.3% | 3.2% | |
| Mar 2026 | $3.35M | +74.5% | +133.4% | 0.6% | |
| Mar 2026 | $2.96M | -84.7% | +96.4% | 0.9% | |
| Mar 2026 | $1.2M | +427.8% | -16.1% | 0.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NAGE) | $10.94M | +20.2% | +8.7% | 3.2% | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.02M | 20.29M | 27.17M | 44.51M | 64.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.23M | 8.48M | 5.23M | 7.77M | 9.74M |
| Inventory | 13.6M | 14.68M | 14.53M | 9.19M | 20.42M |
| Other Current Assets | 200K | 3.12M | 2.6M | 2.63M | 1.85M |
| Total Current Assets | 48.91M | 46.57M | 49.53M | 64.1M | 96.81M |
| Property, Plant & Equipment (Net) | 7.36M | 6.32M | 4.54M | 3.45M | 3.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 857K | 671K | 510K | 359K | 5.66M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 723K | 497K | 383K | 368K | 425K |
| Total Non-current Assets | 8.94M | 7.49M | 5.43M | 4.18M | 9.6M |
| Total Assets | 57.84M | 54.06M | 54.96M | 68.28M | 106.41M |
| Account Payables | 10.42M | 9.68M | 10.23M | 8.53M | 10.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 161K | 157K | 195K | 611K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 8.12M |
| Total Current Liabilities | 17.61M | 17.87M | 20.62M | 17.95M | 19.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.35M | 3.96M | 3.31M | 2.58M | 2.67M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 5.47M |
| Total Non-current Liabilities | 8.5M | 7.52M | 5.89M | 4.24M | 9.95M |
| Total Liabilities | 26.11M | 25.39M | 26.51M | 22.18M | 29.87M |
| Common Stock | 68K | 74K | 75K | 77K | 79K |
| Retained Earnings | (168.95M) | (185.49M) | (190.46M) | (181.91M) | (164.53M) |
| Accumulated OCI | (2K) | (3K) | (4K) | (4K) | (9K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.73M | 28.67M | 28.46M | 46.09M | 76.53M |
| Total Debt | 4.7M | 4.26M | 3.28M | 2.65M | 2.82M |
| Net Debt | (23.32M) | (16.03M) | (23.9M) | (41.86M) | (61.97M) |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.